Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Japan To Reimburse Zolgensma – But At Lower Price Than US

Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.

Japan Gene Therapy Reimbursement

Latest From Pricing Debate

US Medicare Insulin Demo Could Expand To Other Drugs

Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.

Medicare Pricing Debate

US Medicare Insulin Demo Could Expand To Other Drugs

Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.

Medicare Pricing Debate

Medicare's CAR-T Payment Change Helps the Entire Regenerative Medicine Field ... A Little Bit

Alliance for Regenerative Medicine says CMS' plan to create new reimbursement category for CAR-T helps validate entire field, but it may not make it any easier for other products to navigate the payment landscape. ARM is prioritizing value-based payment legislation in its Congressional lobbying.

Gene Therapy Medicare

COVID-19 And The Future Of Rx Pricing Policy: An Interview With White House Advisor Grogan

White House Domestic Policy Council Director Joe Grogan is departing at the end of May. In an interview, he talked about lessons (so far) from the COVID-19 response and the future of drug pricing policy against the backdrop of the pandemic.

Pricing Debate Coronavirus COVID-19

'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill

Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.

Coronavirus COVID-19 Pricing Debate

Gilead’s Second Chance To Re-Set The Drug Price Debate

In 2014, Gilead’s launch of the “$1,000-a-pill” cure for hepatitis C triggered unprecedented political pressure around innovator drug pricing in the US. Now the company has the first effective therapy for COVID-19 – and a chance to re-set the political landscape for drug pricing once again.

Pricing Debate Coronavirus COVID-19

Waste Management: How Amgen’s Kyprolis Packaging Change Could Produce Savings To Medicare

Medicare Part B spending on discarded, weight-based drugs sold in single-use vials is around $725m annually. The National Academies of Science, Engineering and Medicine is evaluating strategies to reduce the waste.

Pricing Debate Medicare

COVID-19 Shifts ICER Pricing Targets, Creating New Hurdles For Drug Developers

With a remdesivir analysis pushing cost-recovery models and lower thresholds for cost-effectiveness, ICER's COVID-19 pricing framework will likely result in lower pricing benchmarks for drugs than the group would have issued under its typical analysis framework. Critics say this is the opposite of what should be incentivized in an emergency.

Coronavirus COVID-19 Cost Effectiveness

AAM Offers Drug Manufacturing Repatriation Plan … For A Price

Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.

Manufacturing Generic Drugs
See All
UsernamePublicRestriction

Register